Stocks · News reference

Kanzhun Sees Q3 Sales $355.190M-$368.454M vs $361.520M Est

Aug 25, 2026, 11:24 AMBenzinga Newsdesk

Kanzhun (NASDAQ:BZ) sees Q3 sales of $355.190 million-$368.454 million vs $361.520 million analyst estimate.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 28, 2026, 6:46 PMBamboo Works
Kanzhun Eyes Brazil, Argentina And Vietnam For Growth
The recruitment app operator’s revenue has slowed steadily over the last three years as it solidifies its dominant position in China image credit: Bamboo Works Key Takeaways: Kanzhun’s revenue grew 14.1%
BZ RHI
BenzingaAug 27, 2026, 3:21 PMBenzinga Newsdesk
Barclays Maintains Overweight on Kanzhun, Raises Price Target to $20
Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $19 to $20.
BZ
BenzingaAug 26, 2026, 2:16 PMAvi Kapoor
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.
ACHC AEO ALHC ANF BZ
BenzingaAug 25, 2026, 4:46 PMBenzinga Newsdesk
Kanzhun shares are trading higher after the company reported better-than-expected Q2 EPS results.
BZ